10-Q: J&J Q1 2026 Sales Rise 9.9%, Driven by Innovative Medicine

Johnson & Johnson reported a 9.9% increase in first-quarter sales to $24.1 billion, with the Innovative Medicine segment showing robust growth, partially offset by declines in Immunology.

Summary

• Johnson & Johnson's sales for the first quarter of 2026 reached $24.1 billion, a 9.9% increase compared to the prior year.
• This growth was driven by an operational increase of 6.4% and a positive currency impact of 3.5%.
• The Innovative Medicine segment reported sales of $15.4 billion, an 11.2% increase, with strong performance in Oncology.
• The MedTech segment contributed $8.6 billion in sales, a 7.7% increase, showing growth across its Cardiovascular, Surgery, Vision, and Orthopaedics franchises.
• Net earnings for the quarter were $5.2 billion, a decrease from $11.0 billion in the prior year, impacted by a significant reversal of a talc reserve in the prior year.
• Earnings per share were $2.14 diluted, down from $4.54 in the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but generally positive report, with strong top-line growth driven by key segments, offset by expected headwinds from biosimilar competition and a significant year-over-year decrease in net earnings due to a prior-year one-time item.

Positives

• Worldwide sales increased by 9.9% to $24.1 billion, driven by operational growth of 6.4% and a positive currency impact of 3.5%.
• The Innovative Medicine segment saw sales grow by 11.2% to $15.4 billion, with Oncology products showing strong operational growth of 17.8%.
• Key Oncology products like CARVYKTI, TECVAYLI, TALVEY, RYBREVANT/LAZCLUZE, and ERLEADA demonstrated significant growth.
• TREMFYA in the Immunology segment grew by 68.3%, driven by market and share gains.
• Neuroscience products, including CAPLYTA, achieved operational growth of 29.3%.
• Pulmonary Hypertension products grew by 10.7%, with UPTRAVI and OPSUMIT/OPSYNVI showing strong performance.
• MedTech segment sales increased by 7.7% to $8.6 billion, with Cardiovascular franchise sales up 13.0% and Abiomed showing 16.3% growth.
• Orthopaedics franchise sales grew by 6.3%, with Hips, Knees, and Trauma showing positive growth.
• The company maintained a strong cash position, with cash and cash equivalents totaling $21.7 billion.

Negatives

• Net earnings decreased significantly to $5.2 billion from $11.0 billion in the prior year, largely due to a $7.0 billion reversal of a talc reserve in Q1 2025.
• Immunology products experienced an operational decline of 11.8%, primarily due to the significant sales decline of STELARA (down 59.7%) due to biosimilar competition.
• IMBRUVICA sales declined by 6.9% due to competitive pressures and unfavorable patient mix.
• XARELTO sales declined by 7.0% due to continued share erosion.
• The MedTech segment's income before tax as a percentage of sales decreased to 14.3% from 17.7% in the prior year.
• The Innovative Medicine segment's income before tax as a percentage of sales decreased to 34.5% from 37.6% in the prior year.

Risks

• Continued biosimilar competition for STELARA is expected to negatively impact sales.
• Generic competition for OPSUMIT is anticipated in the U.S. in the second half of 2026.
• Potential for significant market share and revenue losses if patent litigation for key products is unsuccessful.
• Ongoing legal proceedings, including those related to talc matters, intellectual property, and product liability, could result in material adverse effects on financial results.
• The planned separation of the Orthopaedics business introduces execution risks and potential impacts on future financial performance.
• Global economic conditions, inflation, currency fluctuations, and geopolitical events pose risks to international operations and supply chains.
• Increased scrutiny of the healthcare industry by government agencies could lead to significant penalties.
• Changes in tax laws and regulations could result in additional tax liabilities.

Future Outlook

The company expects to continue paying regular quarterly cash dividends. The planned separation of the Orthopaedics business is targeted for completion within 18 to 24 months of the October 2025 announcement. The company continues to monitor global capital markets and may raise capital when conditions are favorable. The company anticipates that operating cash flows, external funding, borrowing capacity, and access to commercial paper markets will provide sufficient resources for operating needs, including remaining liabilities for talc matters, corporate bonds, and opioid settlements.

Management Comments

• Joaquin Duato, Chief Executive Officer, certified that the report is accurate and fair.
• Joseph J. Wolk, Executive Vice President, Chief Financial Officer, certified that the report is accurate and fair.
• Management concluded that disclosure controls and procedures were effective as of March 29, 2026.

Industry Context

StockSavvy.ai notes that Johnson & Johnson's performance reflects broader industry trends, including the significant impact of biosimilar competition on established drug revenues, as seen with STELARA, and the ongoing growth in specialized oncology and MedTech areas. The company's strategic moves, such as the planned separation of its Orthopaedics business, align with industry consolidation and portfolio optimization strategies.

Legal Proceedings

• Ongoing litigation related to talc matters, with approximately 75,000 plaintiffs in the U.S. and a current reserve of $3.4 billion.
• Securities class action lawsuit filed in February 2018 regarding alleged asbestos contamination in body powders, with the Supreme Court denying a petition for rehearing in October 2025.
• Global settlement agreement with Imerys and Cyprus regarding talc-related disputes, approved in October 2024, with appeals ongoing.
• Patent infringement lawsuits filed against generic manufacturers for XARELTO, INVEGA SUSTENNA, ERLEADA, SPRAVATO, CAPLYTA, and UPTRAVI.
• Litigation concerning alleged infringement of patents related to Impella products by Abiomed.
• Civil investigation by the DOJ under the False Claims Act related to free or discounted intraocular lenses and equipment.
• Qui tam lawsuit alleging off-label promotion of PREZISTA and INTELENCE, with a jury finding liability for a portion of off-label promotion claims in June 2024.
• Civil Investigative Demand from the DOJ regarding management and advisory services for REMICADE or SIMPONI ARIA, with a trial scheduled for November 2026.
• Lawsuit alleging violation of the U.S. Anti-Terrorism Act related to sales practices in Iraq.
• Putative class action alleging breach of fiduciary duties under ERISA regarding the Company's prescription-drug benefits program.
• Lawsuit by former stockholders of Auris Health Inc. alleging breach of contract and fraud in connection with acquisition.
• Antitrust lawsuit alleging restriction of competition in the sale of High Density Mapping Catheters and Ultrasound Catheters.
• Putative class actions alleging antitrust and unfair competition laws violations related to TRACLEER supply.
• Putative class action alleging antitrust law violations for delaying biosimilar competition with STELARA.
• Qui tam complaint alleging violations of the False Claims Act and state law regarding pricing information for ZYTIGA.
• Breach of contract and unjust enrichment claims related to TREMFYA commercialization.

Stakeholder Impact

• Shareholders: Continued regular quarterly cash dividends are expected. The planned separation of the Orthopaedics business may impact future shareholder value and strategic focus.
• Employees: Stock-based compensation plans continue, with related expenses noted. Restructuring programs may impact employment levels in specific areas.
• Creditors: The company has significant debt obligations, with a net debt position of $32.9 billion as of March 29, 2026.
• Suppliers: The company has agreements for supplier finance programs, with confirmed obligations of $0.7 billion as of March 29, 2026.

Next Steps

• Continue to monitor and manage the impact of biosimilar competition on STELARA.
• Prepare for expected generic competition for OPSUMIT in the U.S. in the second half of 2026.
• Continue to explore paths for the separation of the Orthopaedics business, targeting completion within 18-24 months.
• Monitor global capital markets for favorable opportunities to raise capital.
• Continue to manage ongoing legal proceedings and associated liabilities.

Key Dates

Recommendation

The company demonstrates strong revenue growth driven by its Innovative Medicine and MedTech segments, particularly in Oncology and advanced medical devices. However, significant headwinds from biosimilar competition on key products like STELARA, ongoing substantial legal liabilities (especially talc litigation), and a notable decrease in net earnings year-over-year warrant a cautious approach. While the strategic direction and product pipeline remain robust, the uncertainties surrounding litigation and the impact of patent expiries necessitate a 'hold' recommendation until these factors are more clearly resolved or mitigated.

Keywords

Johnson & Johnson, 10-Q, Quarterly Report, Innovative Medicine, MedTech, Oncology, Immunology, Neuroscience, Sales, Net Earnings, Biosimilar Competition, STELARA, CAPLYTA, Talc Litigation